Trust as the Foundation: Advancing AI in Healthcare and Life Sciences

As Healthcare & Life Sciences (HLS) companies accelerate adoption of Generative AI, one pattern is universal: AI delivers value only when users trust it. Clinicians, regulatory reviewers, medical writers, commercial teams, and IT stakeholders repeatedly ask the same foundational questions:

  • Can I trust what the AI is telling me?
  • Is my proprietary data safe?
  • What if the model hallucinates?
  • Who has the final authority?
  • How do we monitor and control this long‑term?

The organizations that deliberately build trust, transparency, and governance into their AI systems from Day 1 see higher adoption, faster time‑to‑value, and lower operational risk.

The clear & consistent narrative that we will be building this over is “Trust is not an afterthought. It is a product requirement.”

With this approach:

  •  AI value is unlocked only when users feel safe and in control.
  • Governance is not a blocker — it is an enabler of scale.
How We Address Recurring Concerns in AI Deployments

Below are the top questions we repeatedly hear from clients — and how a robust, enterprise‑grade implementation addresses them.

1. Explainability

“How does the system justify its recommendations? Can a business user trace the logic back to a specific source document or data point?”

How We Address It:

  • Retrieval-Augmented Generation (RAG) with source-grounding, meaning every AI‑generated answer is tied back to a specific data source (SOP, contract, label, medical content repository, etc.). Users receive not just the answer but also citations, document snippets, and confidence scores.
  • Advanced RAG Pipelines (RAG 2.0 / RAG Fusion / Auto-RAG): multi-step retrieval with re-ranking ensures the model doesn’t rely on shallow search; it finds the most evidence‑rich results. RAG 2.0 retrieves, checks, enriches, and cross-validates information before answering.
  • Full Chain‑of‑Thought Transparency (LLM Observability + Reasoning Traceability): To move beyond simple citations and deliver true explainability, we incorporate LLM Observability platforms (e.g., LangSmith, enterprise agent observability tools from Databricks Mosaic AI, Azure AI Foundry, etc.) to provide end‑to‑end visibility into how the AI arrives at an answer. This includes:

o    The original user question

o    Any internal transformations or refined queries generated by the AI to improve retrieval quality

o    Exactly which documents, sections, and text chunks were retrieved, ranked, and considered

o    The precise prompt constructed for the LLM, including retrieved context

o    The full reasoning trace (Chain‑of‑Thought) of the AI system — including tool calls, scoring steps, and decision checks

o    The final generated answer, with source‑grounding and confidence indicators

  • For predictive models, we use interpretable ML techniques (SHAP, feature-attribution, influence scores). These tools reveal which factors influenced predictions, displayed in plain language dashboards.
  • The system includes an explainability layer that gives business users human-readable rationales for recommendations.

Outcome: Users always see why the model said what it said and understand the lineage, logic, and evidence behind every AI recommendation — without needing technical expertise.

2. Data Privacy & Proprietary Information Security

“Will our proprietary commercial data (pricing, claims, rebates, trade secrets) be used to train the foundation models of the AI provider?”

How We Address It:

  • Enterprise AI deployments use data isolation — customer data stays within the customer boundary and is not used to train provider foundation models.
  • Private LLMs / Enterprise Models – Models run inside the client’s Azure/AWS/GCP environment warded off from public models.
  • Model Shielding / Privacy Proxies – AI queries pass through a privacy layer that strips identifiers and sensitive attributes. Think of it as a security checkpoint before your data reaches the model.
  • Role-Aware Retrieval – Retrieval agents only fetch content based on the user’s access tier (Commercial, Medical, Reg, etc.).
  • Zero Retention by Default – Prompts, outputs & embeddings aren’t stored unless explicitly configured by the client.
  • All data processing occurs under the organization’s security, compliance, and retention policies.

Outcome: Your data stays fully isolated, encrypted, and never used to train external LLMs — never used to train global models.

3. Hallucination & Risk Controls

“What guardrails prevent the AI from hallucinating responses in bids, RFPs, or medical information outputs?”

How We Address It:

  • Grounded RAG ensures the model only answers from approved content sources.
  • Safety filters block responses when:
    Data sources do not contain an answer
    The confidence is below threshold
    The question falls outside an allowed domain
  • We configure domain-specific policy engines to constrain allowed actions.
  • Outputs for regulated workflows (MI, promo, HEOR, safety) go through:
    Validation rules
    Mandatory citation checks
    Version-controlled knowledge repositories

High-risk workflows have no‑answer fallback instead of fabricated output.

Outcome: AI answers only what it knows — and never invents information.

4. Human Authority & Workflow Design

“Can the AI perform high-stakes actions autonomously? Is human approval mandatory?”

How We Address It:

  • All enterprise workflows follow a Human‑in‑the‑Loop (HITL) or Human‑on‑the‑Loop (HOTL) model.
  • High-stakes activities (e.g., bid submissions, pricing recommendations, medical content drafting) require explicit human approval.
  • Approval steps are auditable with:
    Timestamps
    Reviewer identity
    Version history
  • AI assists with drafting, summarizing, or analyzing — not final action.
    Outcome: Humans remain accountable. AI augments decisions, never replaces them. AI acts as a co-pilot — humans remain the final decision-makers.

5. Reliability, Monitoring & Model Drift

“How do we ensure ongoing accuracy? How do we detect drift?”

How We Address It:

  • We deploy continuous model performance monitoring, including:
    Drift detection (data, concept, prediction drift) – Are the inputs the model sees today different from what it was originally trained or aligned on? Has the “meaning” of the data changed (e.g., new market rules, label updates, competitor activity)? Are the model’s answers suddenly different or less accurate than before?
    Observability dashboards – dashboards that show Accuracy over time, Hallucination rates, Citation coverage, Retrieval quality, etc.
    Automated checks for stale data sources – For RAG use cases, most errors come from old documents or expired medical/promotional content. So, it’s important to track document versions, flag stale or unpublished content or rebuild indexes if source content changes. This ensures the AI never answers from outdated or unapproved materials.
  • Every model follows a defined lifecycle — just like validated systems in regulated environments.
    Scheduled re-evaluations (monthly/quarterly or event‑driven)
    Regression testing to check that new updates haven’t broken anything
    Performance benchmarking on gold‑standard test sets
    Periodic fine‑tuning or parameter updates if new data or rules emerge
  • RAG pipelines include content freshness monitoring (alerts when source documents in Veeva/EDM/DAM change) and metadata tagging (Tracks author, version, date, approval status, etc.). This ensures the AI is always answering from the right sources, not just the nearest vector match.

Outcome: The system stays accurate, current, and trustworthy as business conditions, regulations, and scientific information evolve.

6. Ethics, Fairness & Bias Mitigation

“How do you ensure the AI does not introduce bias in commercial decisions or segmentation?”

How We Address It:

  • Bias testing is integrated at model training and validation stages.
  • Protected attributes (race, gender, etc.) are excluded from decision logic.
  • Models undergo fairness audits, scenario testing, and sensitivity analysis.
  • Bias Monitoring Agents: AI agents scan outputs periodically for patterns of bias and report anomalies.
  • Counterfactual Testing: Simulates alternate scenarios to detect any unintended bias (e.g., “Would the same recommendation be made if the customer profile changed?”).
  • Transparent logic ensures commercial team visibility into why customers or segments are prioritized.
  • Governance boards (Ethics, Legal, Compliance) are part of approval workflows. Models avoid disallowed content categories automatically.

Outcome: AI supports equitable decisions aligned with compliance and organizational values.

7. Access Controls & Information Security

  • Contextual Access Agents: AI determines access based on user role + content sensitivity levels.
  • Fine-grained retrieval permissions: each document chunk has its own access rules.

8. Scientific Accuracy & Source Integrity

  • Cross-verification across multiple sources before providing an answer.
  • Scientific QA Agents that validate evidence strength, study relevance, and compliance rules.
Market Adoption Snapshots
  • Veeva AI (2025) is embedding application‑specific AI agents into Vault apps with safeguards and direct access to validated content—positioning explainability and auditability within existing clinical/reg/safety/commercial workflows rather than a bolt‑on layer.
  • Vertex AI (Google Cloud) promotes model registry + monitoring aligned to GxP governance (traceability, change control)—practical for life‑sciences model inventory and audit readiness.
  • Azure AI Foundry: configurable guardrails and content filters + groundedness (preview); agent guardrails scan tool calls and responses
  • Veeva AI Agents are being delivered inside Vault apps with application‑specific prompts and safeguards, making it natural to keep HITL/HOTL approvals in MLR/PRC processes.
  • IQVIA’s “Healthcare‑grade AI” emphasizes privacy, quality, and trust; external recognition notes their responsible governance posture while scaling GenAI across R&D and commercialization.
  • Cloud providers are converging on shared‑fate security (customer isolation + built‑in guardrails) to satisfy EU AI Act/FDA/EMA governance and HLS internal infosec.
Industry Outlook: Where the Market Is Headed (and Who’s Catching Up)
  • From pilots to scale—slow but accelerating. Surveys show nearly all pharma/medtech players have tried GenAI; ~1/3 are scaling, but only a small fraction realize sustained value. The gap is operating model + governance + reliability—not model capability.
  • Agentic shift. 2025–2026 sees a move from “chatbots” to agentic systems with orchestrators, verifier agents, and policy‑aware tool‑use. Leaders (Databricks, Microsoft, Google, Veeva) are baking guardrails + observability into platforms; late adopters are retrofitting guardrails after the fact.
  • Regulatory clarity is rising. FDA (2025 drafts) and FDA‑EMA (2026 principles) are codifying credibility, lifecycle, and transparency—pushing industry toward documented provenance, change control, and monitoring.
  • Provider ecosystems & partnerships. AWS x General Catalyst, IQVIA x NVIDIA, and cloud‑HLS collaborations are accelerating production‑grade agentic solutions; firms without cloud + data modernization are now playing catch‑up.
  • Platformization inside HLS stacks. Veeva’s move to embedded agents across Vault apps signals a future where AI is native to quality/regulatory/clinical/commercial systems—not an external addon.
Summary: A Trust‑First Framework for Responsible AI Adoption

Building trust with business users is the #1 determinant of AI success. Our approach ensures:

  • Explainable, auditable outputs
  • Zero data leakage into foundation models
  • Strict hallucination guardrails
  • Human‑approval workflows for high‑stakes actions
  • Continuous monitoring to prevent model drift
  • Ethical, bias‑free decision-making

This approach gives organizations the confidence to scale AI safely across commercial, medical, regulatory, and operational use cases — achieving higher ROI without compromising compliance or patient impact.

Author Details

Inder Neel Dua

Inder is Partner at Infosys Consulting and leads the Life Sciences unit. With over 18 years of consulting expertise, he specializes in Listening, Communication and Solutioning business objectives with practical implementation. Inder likes to simplify complex information, develop effective frameworks, and streamline delivery through change management and operational effectiveness.

Pragnya Koya

Pragnya is a Business Consulting professional with 4+ years of experience in the Healthcare and Life Sciences sectors. She brings a robust blend of expertise in product development, performance reporting and improvement, and customer experience enhancement, consistently leveraging strong data management and analytical skills to drive tangible results.

Rishit Thakkar

Rishit is a Data Analytics and AI professional with 20 yrs of exp. He leads AI CoE for LS vertical at Infosys Consulting. His main focus has been process reimagination using AI and providing AI Solutions across Life Sciences Value Chain. Rishit has performed in various roles including AI Product Owner and AI Project Manager. 

Leave a Comment

Your email address will not be published. Required fields are marked *